Partners & Business Development
BioCryst is constantly seeking to expand and improve its therapeutic development pipeline. It utilizes strategic partnerships early in the drug identification process through in-licensing of drug targets. BioCryst has also established collaborative relationships for the development and commercialization of product candidates to expand its geographic reach beyond the United States.
BioCryst offers potential partners the opportunity to leverage its expertise in structure-guided drug design, which incorporates multiple scientific disciplines including biology, crystallography, medicinal chemistry and computer modeling, in order to most efficiently develop new therapeutic candidates.
If you are interested in contacting BioCryst regarding partnering opportunities, please email the Business Development team at businessdevelopment@BioCryst.com.
Seqirus (formerly CSL Limited)
In June 2015, BioCryst announced that it licensed to Seqirus RAPIVAB® (peramivir injection) for the treatment of influenza in all territories, excluding Japan, Taiwan, Israel and Korea
Shionogi & Co., Ltd.
In March 2007, BioCryst entered into an exclusive license agreement to develop and commercialize peramivir in Japan and Taiwan for the treatment of influenza. An intravenous formulation of peramivir has been marketed under the commercial name RAPIACTA® for the treatment of adults, children and infants with influenza since 2010.
Green Cross Corporation
In June 2006, BioCryst and Green Cross Corp. entered into an agreement to develop and commercialize peramivir in Korea. Green Cross Corp. announced in August 2010 that it had received marketing and manufacturing authorization for i.v. peramivir in Korea to treat patients with influenza A & B viruses, including pandemic H1N1 and avian influenza.
Neopharm Group for Israel
In March 2011, BioCryst and the Neopharm Group entered into an agreement to sell & distribute peramivir in Israel. Neopharm is a leading provider of integrated solutions across the healthcare spectrum and the second largest provider in the Isralei healthcare market.
In November 2011, BioCryst and Mundipharma amended their 2006 licensing agreement to grant Mundipharma exclusive worldwide rights to develop and commercialize forodesine in the field of oncology.